The Petya cyber-attack will cost hundreds of millions of dollars in second half
The U.K. insurance group will focus on retirement products.
The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.
U.K. minister says she has not yet had time to consider all responses to her consultation on referring the $15 billion takeover of the satellite broadcaster to the competition regulator.
Investors believe Bain and Cinven or a rival consortium could still return for another run at the German generics company, despite the failure of their $6 billion offer.